Left ventricular hypertrophy and geometry in type 2 diabetes patients with chronic kidney disease. An echocardiographic study

Cardiovascular Journal of Africa

Volumn 23, Issue 2, 2012, Pages 73-77

  Bayauli, M P ^a   Lepira, F B ^a   Kayembe, P K ^b   M'buyamba Kabangu, J R ^a  

^a University of Kinshasa Hospital   (Congo)

^b UNIVERSITY OF KINSHASA   (Congo)

Author keywords

Chronic kidney disease; Left ventricular hypertrophy; Predictors; Prevalence; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CREATININE; GLUCOSE;

ADULT; ANTHROPOMETRY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE SEPTUM; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

AGED; CROSS-SECTIONAL STUDIES; DEMOCRATIC REPUBLIC OF THE CONGO; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; VENTRICULAR REMODELING;

EID: 84859049987     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2011-028     Document Type: Article

References (38)

1. Srivastava PM, Calafiore P, Macisaac RJ, Patel SK, Thomas MC, Jerums G, Burell LM. Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with type 2 diabetes. Clin Sci 2008; 114(4): 313-320. (Pubitemid 351294007)
2. Foppa M, Duncan BB, Arnett DK, Benjamin EJ, Liebson PR, Manolio TA, Skelton TN. Diabetes, gender, and left ventricular structure in African-Americans: the atherosclerosis risk in communities study. Cardiovasc Ultrasound 2006; 4: doi: 10. 1186/1476-7210-4-43.
3. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002; 17(Suppl. 1): 29-36. (Pubitemid 34157116)
4. Berl T, Henrick W. Kidney-heart interactions: epidemiology, pathogenesis and treatment. Clin J Am Soc Nephrol 2006; 1: 8-18.
5. Schiffrin E, Lipman ML, Mann JFE. Chronic kidney disease. Effects on the cardiovascular system. Circulation 2007; 116: 85-97.
6. Ulasi II, Arodiwe EB, Ijoma CK. Left ventricular hypertrophy in African black patients with chronic renal failure at first evaluation. Ethn Dis 2006; 16(4): 859-864.
7. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003; 16(2): 101-105. (Pubitemid 37361072)
8. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in non diabetic predialysis chronic kidney disease. Am J Kidney Dis 2005; 46(2): 320-327. (Pubitemid 41040362)
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-cholrsterol without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-508.
10. National Heart Lung and Blood Institute. Executive Summary of the Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
11. Levey AS, Greene T, Kusek JW. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephol 2000; 11: A0828.
12. K/DOQI, Clinical practical guidelines for chronic kidney disease (CKD): Evaluation, Classification and Stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39(2 Suppl): S22-26.
13. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083. (Pubitemid 9091990)
14. Devereux RB, Alonso DR, Lucas EM, Gottlieb E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458. (Pubitemid 16119719)
15. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitidis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260.
16. Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J, Feinlib M, Castelli WP. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. Circulation 1987; 75: 126-133.
17. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiopgraphic correlations in the presence of absence in the presence of absence of synergy. Am J Cardiol 1976; 37: 7-11.
18. Lu B, Song X, Dong X, Yang Y, Zhang Z, Wen J, et al. High prevalence of chronic kidney disease in population-based patients diagnosed with type 2 diabetes in downtown Shangai. J Diabetes Complic 2008; 22(2): 96-103. (Pubitemid 351226620)
19. Lemley KV. Diabetes and chronic kidney disease: lessons from the Pima Indians. Pediatr Nephrol 2008; 23(1): 1933-1940.
20. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007; 55(6): 498-510. (Pubitemid 46962309)
21. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities- the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381. (Pubitemid 26049592)
22. Ritz E. Metabolic syndrome and kidney disease. Blood Purif 2008; 26(1): 59-62.
23. Paravivini TM, Touyz RM. NAD (P) Hoxidase, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008; 31 (Suppl. 2): S170-S180.
24. Kis E, Cseprekal O, Horvath Z, Katona G, Fekete BC,Hrapka L, et al. Pulse pressure velocity in end-stage renal disease: influence of age and body dimensions. Pediatr Res 2008; 63(1): 95-98.
25. Minutolo R, Borrelli S, Chiodini P, Scigliano R, Bellizzi V, Cianciaruso B, et al. Effects of age on hypertensive status in patients with chronic kidney disease. J Hypertens 2007; 25(11): 2325-2333. (Pubitemid 47537928)
26. Laurent S, Boutouyrie P. Arterial Stiffness: ane surrogate end point for cardiovascular disease. J Nephrol 2007; 20(Suppl. 12): S45-S50. (Pubitemid 351266137)
27. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F, for the MMKD study group. Uric acid as a risk factor for progression of non diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 2008; 43(4): 347-352.
28. Nardi E, Cottone S, Mule G, Palermo A, Cusiman P, Cerasola G. Influence of chronic renal insufficiency on left ventricular diastolic function in hypertensives without left ventricular hypertrophy. J Nephrol 2007; 20(3): 320-328. (Pubitemid 47570362)
29. Agaba El. Characteristics of type 2diabetics presenting with end-stage renal disease at the Jos University Hospital, Nigeria. West Afr J Med 2004; 23(2): 142-145.
30. Alebiosu CO, Odusan O, Familoni OB, Juiyesimi AE. Cardiovascular risk factors intype 2 diabetic Nigerians with clinical diabetic nephropathy. Cardiovasc J S Afr 2004; 15(3): 124-128. (Pubitemid 39056140)
31. Kanda T, Wakino S, Hayashi K, Plutzky J. Cardiovascular disease and type 2 diabetes mellitus: Procceeding with caution at a dangerous intersection. J Am Soc Nephrol 2008; 19: 4-7.
32. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47(2): 195-202. (Pubitemid 43189763)
33. Ha SK, Park HS, Kim SJ, Park CH, Kim DS, Kim HS. Prevalence and patterns of left ventricular hypertrophy in patients with predialysis chronic renal failure. J Korean Med Sci 1998; 13: 488-494. (Pubitemid 128686238)
34. Aje A, Adedeyi AA, Oladapo OO, Dada A, Ogah US, Ojji DB, Falase AD. Left ventricular patterns in newly presenting Nigerian hypertensives: An echocardiographic study. BMC Cardiovasc Disorders 2006; 6: 4.
35. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005; 45: 991-996. (Pubitemid 40628949)
36. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary Transforming Growth Factor beta and the progression of chronic kidney disease. Am J Nephrol 2007; 27(5): 435-440. (Pubitemid 47481999)
37. Choncol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50(2): 239-247. (Pubitemid 47095076)
38. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzoli, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897. (Pubitemid 35386908)